Sort By

Xarelto Litigation Progresses Amid Growing Sales

pharmacist helping an elderly woman

Johnson & Johnson and Bayer’s blockbuster blood thinner Xarelto continues to post impressive sales numbers. But, the number of people filing lawsuits against the drug’s makers is also growing. Thousands of plaintiffs claim J&J and Bayer hid the danger of uncontrolled bleeding and engaged in misleading advertising.

Xarelto is still the most prescribed drug in its class in the U.S. and will remain the top drug well into 2022 in Europe, EvaluatePharma analysts report. Though sales remain strong, some experts still worry about heavy bleeding side effects caused by the drug. In some cases, uncontrolled bleeding can be fatal. The bleeding side effects led to a surge in lawsuits.

“The number of pending product liability lawsuits continues to increase, and the Company continues to receive information with respect to potential costs and the anticipated number of cases,” J&J said in its 2015 Annual report.

As of May 2016, there were 5,260 claims pending in federal court in the Eastern District of Louisiana before Judge Eldon E. Fallon. Plaintiffs claim a number of side effects were caused by Xarelto, including strokes, blood clots and hemorrhages.

Bellwether Cases Selected

Out of over 5,000 cases, Judge Fallon gathered 40 into a preliminary pool for bellwether trials in January 2016. Plaintiff and defendant attorneys choose these cases as the most representative of the entire group. Bellwethers can help predict how cases are like to proceed.

According to court documents, Judge Fallon announced the first 4 cases set for trial from this initial group. The trials are set to being in early 2017. The judge scheduled the first two for February 6 and March 13. The second pair will proceed on April 24 and May 30.

Ellen Relkin, a member of the plaintiff’s steering committee for the Louisiana MDL, says that a big problem with Xarelto is its “one-size-fits-all” design.

“[A] problem with the medication is it has what is called ‘a low therapeutic index.’ In other words, it can be safe at a certain point and dangerous within a very close range,” Relkin previously told Drugwatch. “Someone can be 110 pounds or 200 pounds, old or young [and] with varying kidney functions and get the same dose and have a very different impact.”

Xarelto Claims May Follow in Pradaxa’s Example

While experts say it is too early to predict the future of thousands of Xarelto claims, attorneys say these claims may follow a similar path to Pradaxa claims.

Pradaxa, a similar blood thinner manufactured by Boehringer Ingelheim, faced thousands of lawsuits for uncontrolled bleeding. In 2014, the drug maker settled all state and federal lawsuits for $650 million.

Before the Xarelto cases come close to settling, attorneys say the Xarelto multidistrict litigation will continue to grow.

“I expect to see an increase in filings over the next month or two given the media attention caused by The New York Times’ recent report, but on the whole this is now a stable mass tort that is reasonably well known,” Philadelphia attorney Max Kennerly told Forbes.

Kennerly is involved in the group of Philadelphia cases, which is separate from the federal MDL in Louisiana.

“Philly has just set up a deposition protocol [in March], so they are some time away from getting near trial-ready. I would expect a Philly bellwether [trial] in summer 2017 or later,” he said.

Last modified: February 21, 2017


Michelle Y. Llamas is a senior content writer. She is also the host of Drugwatch Podcast where she interviews medical experts as well as patients affected by drugs and medical devices. She has written medical and legal content for several years — including an article in The Journal of Palliative Medicine and an academic book review for Nova Science Publishers. With Drugwatch, she has developed relationships with legal and medical professionals as well as with several patients and support groups. Prior to writing for Drugwatch, she spent several years as a legal assistant for a personal injury law firm in Orlando. She obtained her English – Technical Communication degree from the University of Central Florida. She is a committee member with the American Medical Writers Association.

Hide Sources

  1. Malfitana, N. (2016, May 20). With First Trials On Horizon, Value Of Growing Philly Xarelto Claims Uncertain. Forbes. Retrieved from
  2. Staton, T. (2016, May 2). Xarelto, Xtandi surge toward Europe's best-selling ranks, with Opdivo close behind. FiercePharma. Retrieved from
  3. Johnson & Johnson. (2015). Annual Report 2015. Retrieved from